Advertisement

Der Internist

, Volume 58, Issue 11, pp 1133–1141 | Cite as

Chronische Atemwegskolonisierung mit Pseudomonas aeruginosa bei Mukoviszidose

Ansätze zur Prävention
  • A.-M. DittrichEmail author
Schwerpunkt: Chronische Atemwegsinfektionen

Zusammenfassung

Pseudomonas aeruginosa (PsA) ist ein Leitkeim der Lungenerkrankung bei Mukoviszidose/zystischer Fibrose („cystic fibrosis“, CF). Die chronische Besiedlung mit PsA ist ein zentraler Faktor für den Verlauf der Lungenerkrankung bei CF. PsA trägt maßgeblich zu Morbidität und Mortalität bei, beeinflusst aber auch Lebensqualität und Kosten der Behandlung. Das Verhindern der chronischen Besiedlung stellt schon lange ein zentrales Anliegen in der Behandlung von CF-Patienten dar. Im vorliegenden Artikel werden Studien erörtert, die Hinweise dafür liefern, dass die chronische Besiedlung mit PsA verhindert werden kann. Maßnahmen, die dazu beitragen können, die chronische PsA-Besiedlung zu verhindern, werden kritisch beleuchtet und Handlungsempfehlungen abgeleitet.

Schlüsselwörter

Mukoviszidose/Zystische Fibrose Mikrobiologie Pseudomonas aeruginosa Chronische Besiedlung Prävention 

Chronic Pseudomonas aeruginosa airway colonization in cystic fibrosis patients

Prevention concepts

Abstract

Pseudomonas aeruginosa (PsA) is a hallmark pathogen of the lung disease in cystic fibrosis (CF) patients. Chronic PsA colonization is a central factor in the course of CF lung disease. PsA contributes considerably to morbidity and mortality, and also has a significant impact on quality of life and the costs of CF treatment. Prevention of chronic colonization has therefore been a major goal in the treatment of CF patients for many years now. In the present article, studies are presented which suggest that prevention of chronic colonization can be achieved. Approaches to prevent chronic PsA colonization are critically evaluated and recommendations for preventative approaches are generated from this discussion.

Keywords

Cystic fibrosis Microbiology Pseudomonas aeruginosa Chronic colonization Prevention 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

A.-M. Dittrich gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Amin R, Lam M, Dupuis A, Ratjen F (2011) The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr Pulmonol 46:554–558CrossRefPubMedGoogle Scholar
  2. 2.
    Blanchard AC, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F (2017) Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 16:395–400CrossRefPubMedGoogle Scholar
  3. 3.
    Ciofu O, Hansen CR, Hoiby N (2013) Respiratory bacterial infections in cystic fibrosis. Curr Opin Pulm Med 19:251–258CrossRefPubMedGoogle Scholar
  4. 4.
    Clifton IJ, Fletcher LA, Beggs CB, Denton M, Conway SP, Peckham DG (2010) An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. J Cyst Fibros 9:64–68CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen-Cymberknoh M, Gilead N, Gartner S, Rovira S, Blau H, Mussaffi H, Rivlin J, Gur M, Shteinberg M, Bentur L, Livnat G, Aviram M, Picard E, Tenenbaum A, Armoni S, Breuer O, Shoseyov D, Kerem E (2016) Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosis. J Cyst Fibros 15:776–782CrossRefPubMedGoogle Scholar
  6. 6.
    Crull MR, Ramos KJ, Caldwell E, Mayer-Hamblett N, Aitken ML, Goss CH (2016) Change in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time. BMC Pulm Med 16:176CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Doring G, Jansen S, Noll H, Grupp H, Frank F, Botzenhart K, Magdorf K, Wahn U (1996) Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 21:90–100CrossRefPubMedGoogle Scholar
  8. 8.
    Elborn JS (2013) Personalised medicine for cystic fibrosis: treating the basic defect. Eur Respir Rev 22:3–5CrossRefPubMedGoogle Scholar
  9. 9.
    Foundation UCF (2016) Annual Data Report 2015Google Scholar
  10. 10.
    Frederiksen B, Koch C, Hoiby N (1997) Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23:330–335CrossRefPubMedGoogle Scholar
  11. 11.
    Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW (2007) Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol 42:610–623CrossRefPubMedGoogle Scholar
  12. 12.
    Hansen SK, Rau MH, Johansen HK, Ciofu O, Jelsbak L, Yang L, Folkesson A, Jarmer HO, Aanaes K, von Buchwald C, Hoiby N, Molin S (2011) Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. ISME J 6:31–45.  https://doi.org/10.1038/ismej.2011.83 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Harun SN, Wainwright C, Klein K, Hennig S (2016) A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev 20:55–66PubMedGoogle Scholar
  14. 14.
    Hery-Arnaud G, Nowak E, Caillon J, David V, Dirou A, Revert K, Munck MR, Frachon I, Haloun A, Horeau-Langlard D, Le Bihan J, Danner-Boucher I, Ramel S, Pelletier MP, Rosec S, Gouriou S, Poulhazan E, Payan C, Ferec C, Rault G, Le Gal G, Le Berre R (2017) Evaluation of quantitative PCR for early diagnosis of Pseudomonas aeruginosa infection in cystic fibrosis: a prospective cohort study. Clin Microbiol Infect 23:203–207CrossRefPubMedGoogle Scholar
  15. 15.
    Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, Radey M, Accurso FJ, Wolter DJ, Cooke G, Adam RJ, Carter S, Grogan B, Launspach JL, Donnelly SC, Gallagher C, Bruce JE, Stoltz D, Welsh MJ, Hoffman LR, McKone EF, Singh PK (2017) Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. Am J Respir Crit Care Med.  https://doi.org/10.1164/rccm.201609-1954OC PubMedGoogle Scholar
  16. 16.
    Hoiby N, Bjarnsholt T, Moser C, Jensen PO, Kolpen M, Qvist T, Aanaes K, Pressler T, Skov M, Ciofu O (2017) Diagnosis of biofilm infections in cystic fibrosis patients. APMIS 125:339–343CrossRefPubMedGoogle Scholar
  17. 17.
    Johansen HK, Gotzsche PC (2008) Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev CD001399.  https://doi.org/10.1002/14651858.cd001399 Google Scholar
  18. 18.
    Kenny SL, Shaw TD, Downey DG, Moore JE, Rendall JC, Elborn JS (2014) Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis. BMJ Open Respir Res 1:e21CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kozlowska WJ, Bush A, Wade A, Aurora P, Carr SB, Castle RA, Hoo AF, Lum S, Price J, Ranganathan S, Saunders C, Stanojevic S, Stroobant J, Wallis C, Stocks J, London Cystic Fibrosis C (2008) Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis. Am J Respir Crit Care Med 178:42–49CrossRefPubMedGoogle Scholar
  20. 20.
    Langton Hewer SC, Smyth AR (2017) Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 4:CD4197PubMedGoogle Scholar
  21. 21.
    Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM (2003) Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2:29–34CrossRefPubMedGoogle Scholar
  22. 22.
    Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP (2004) Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 37:104–110CrossRefPubMedGoogle Scholar
  23. 23.
    Mayer-Hamblett N, Ramsey BW, Kulasekara HD, Wolter DJ, Houston LS, Pope CE, Kulasekara BR, Armbruster CR, Burns JL, Retsch-Bogart G, Rosenfeld M, Gibson RL, Miller SI, Khan U, Hoffman LR (2014) Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis. Clin Infect Dis 59:624–631CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW (2017) Risk factors for mortality before age 18 years in cystic fibrosis. Pediatr Pulmonol 52(7):909–915CrossRefPubMedGoogle Scholar
  25. 25.
    McPherson H, Rosenthal M, Bush A (2010) Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis? Pediatr Pulmonol 45:566–568PubMedGoogle Scholar
  26. 26.
    Moran Losada P, Chouvarine P, Dorda M, Hedtfeld S, Mielke S, Schulz A, Wiehlmann L, Tummler B (2016) The cystic fibrosis lower airways microbial metagenome. ERJ Open Res 2(2):00096-2015.  https://doi.org/10.1183/23120541.00096-2015 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Müller FM BJ, Rietschel E (2013) S3-Leitlinie „Lungenerkrankung bei Mukoviszidose“: Modul 1: Diagnostik und Therapie nach dem ersten Nachweis von Pseudomonas aeruginosa. AWMF Online.  https://doi.org/10.1016/b978-3-437-22061-6.50533-4
  28. 28.
    Nährlich LBM, Wiese B (2017) Deutsches Mukoviszidoseregister Berichtsband 2015Google Scholar
  29. 29.
    Nilsson E, Larsson A, Olesen HV, Wejaker PE, Kollberg H (2008) Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr Pulmonol 43:892–899CrossRefPubMedGoogle Scholar
  30. 30.
    Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K (2001) Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 138:699–704CrossRefPubMedGoogle Scholar
  31. 31.
    Pitchford KC, Corey M, Highsmith AK, Perlman R, Bannatyne R, Gold R, Levison H, Ford-Jones EL (1987) Pseudomonas species contamination of cystic fibrosis patients’ home inhalation equipment. J Pediatr 111:212–216CrossRefPubMedGoogle Scholar
  32. 32.
    Quittner AL, Sawicki GS, McMullen A, Rasouliyan L, Pasta DJ, Yegin A, Konstan MW (2012) Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res 21:1267–1278CrossRefPubMedGoogle Scholar
  33. 33.
    Ramsay KA, Sandhu H, Geake JB, Ballard E, O’Rourke P, Wainwright CE, Reid DW, Kidd TJ, Bell SC (2017) The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. J Cyst Fibros 16:70–77CrossRefPubMedGoogle Scholar
  34. 34.
    Ratjen F, Munck A, Kho P, Angyalosi G (2010) Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 65:286–291 (for the EPIC Study Group)CrossRefPubMedGoogle Scholar
  35. 35.
    Rosenfeld M, Emerson J, McNamara S, Thompson V, Ramsey BW, Morgan W, Gibson RL (2012) Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 11:446–453 (for the EPIC Study Group)CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Salsgiver EL, Fink AK, Knapp EA, LiPuma JJ, Olivier KN, Marshall BC, Saiman L (2016) Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 149:390–400CrossRefPubMedGoogle Scholar
  37. 37.
    Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182:627–632CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Schneider EK, Azad MA, Han ML, Zhou TQ, Wang J, Huang JX, Cooper MA, Doi Y, Baker MA, Bergen PJ, Muller MT, Li J, Velkov T (2016) An „unlikely“ pair: the antimicrobial synergy of polymyxin B in combination with the cystic fibrosis transmembrane conductance regulator drugs KALYDECO and ORKAMBI. ACS Infect Dis 2:478–488CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Simon A (2012) Anforderungen an die Hygiene bei der medizinischen Versorgung von Patienten mit Cystischer Fibrose (Mukoviszidose). mhp, WiesbadenGoogle Scholar
  40. 40.
    Taccetti G, Campana S, Festini F, Mascherini M, Doring G (2005) Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26:458–461CrossRefPubMedGoogle Scholar
  41. 41.
    Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Early Pseudomonas Infection Control I (2011) Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 165:847–856CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Troxler RB, Hoover WC, Britton LJ, Gerwin AM, Rowe SM (2012) Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatr Pulmonol 47:1113–1122CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    The UK Cystic Fibrosis Trust Infection Control Group (2004) Pseudomonas aeruginosa infection in people with cystic fibrosis: suggestions for prevention and controlGoogle Scholar
  44. 44.
    The UK Cystic Fibrosis Trust Infection Control Group (2016) UK CF Registry: Annual Data Report 2015Google Scholar
  45. 45.
    Valerius NH, Koch C, Hoiby N (1991) Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 338:725–726CrossRefPubMedGoogle Scholar
  46. 46.
    Wainwright CE, Vidmar S, Armstrong DS, Byrnes CA, Carlin JB, Cheney J, Cooper PJ, Grimwood K, Moodie M, Robertson CF, Tiddens HA (2011) Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 306:163–171 (for the ACFBAL Study Investigators)PubMedGoogle Scholar
  47. 47.
    Whiteson KL, Bailey B, Bergkessel M, Conrad D, Delhaes L, Felts B, Harris JK, Hunter R, Lim YW, Maughan H, Quinn R, Salamon P, Sullivan J, Wagner BD, Rainey PB (2014) The upper respiratory tract as a microbial source for pulmonary infections in cystic fibrosis. Parallels from island biogeography. Am J Respir Crit Care Med 189:1309–1315CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, von der Hardt H (1998) Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 25:88–92CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH 2017

Authors and Affiliations

  1. 1.Klinik für pädiatrische Pneumologie, Allergologie und NeonatologieMedizinische Hochschule HannoverHannoverDeutschland

Personalised recommendations